AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
chlormezanone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 603 | 80-77-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.60 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 99 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| S (Water solubility) | 2.50 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 20, 1960 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Food allergy | 1319.08 | 197.14 | 351 | 10632 | 25127 | 90592337 |
| Immunodeficiency | 1161.02 | 197.14 | 357 | 10626 | 42877 | 90574587 |
| Temperature regulation disorder | 1113.22 | 197.14 | 274 | 10709 | 14305 | 90603159 |
| Rash erythematous | 862.35 | 197.14 | 316 | 10667 | 64788 | 90552676 |
| Hyperhidrosis | 762.01 | 197.14 | 357 | 10626 | 135948 | 90481516 |
| Coeliac disease | 682.09 | 197.14 | 241 | 10742 | 44369 | 90573095 |
| Upper respiratory tract infection | 667.57 | 197.14 | 320 | 10663 | 127998 | 90489466 |
| Prescribed overdose | 656.37 | 197.14 | 291 | 10692 | 97334 | 90520130 |
| Fluid retention | 642.15 | 197.14 | 278 | 10705 | 87813 | 90529651 |
| Foetal death | 610.14 | 197.14 | 184 | 10799 | 20539 | 90596925 |
| Intentional product misuse | 592.22 | 197.14 | 264 | 10719 | 89340 | 90528124 |
| Overdose | 504.75 | 197.14 | 284 | 10699 | 157425 | 90460039 |
| Asthma | 472.94 | 197.14 | 318 | 10665 | 241842 | 90375622 |
| Exposure during pregnancy | 458.16 | 197.14 | 310 | 10673 | 238100 | 90379364 |
| Hepatic enzyme increased | 436.70 | 197.14 | 355 | 10628 | 360381 | 90257083 |
| Bursitis | 428.87 | 197.14 | 240 | 10743 | 131414 | 90486050 |
| Hypersensitivity | 358.06 | 197.14 | 351 | 10632 | 454326 | 90163138 |
| Product use issue | 329.49 | 197.14 | 291 | 10692 | 329628 | 90287836 |
| Thrombocytopenia | 325.15 | 197.14 | 239 | 10744 | 208486 | 90408978 |
| Erythema | 296.53 | 197.14 | 235 | 10748 | 229011 | 90388453 |
| Psoriasis | 294.80 | 197.14 | 197 | 10786 | 147557 | 90469907 |
| Constipation | 263.13 | 197.14 | 239 | 10744 | 280156 | 90337308 |
| Infusion related reaction | 262.95 | 197.14 | 286 | 10697 | 416494 | 90200970 |
| Back pain | 238.04 | 197.14 | 239 | 10744 | 316936 | 90300528 |
| Hypertension | 231.19 | 197.14 | 280 | 10703 | 457252 | 90160212 |
| Contraindicated product administered | 218.02 | 197.14 | 229 | 10754 | 319910 | 90297554 |
| Joint swelling | 199.21 | 197.14 | 273 | 10710 | 503027 | 90114437 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Post procedural infection | 62.21 | 57.81 | 11 | 99 | 5774 | 42615451 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Temperature regulation disorder | 1090.11 | 198.25 | 240 | 8020 | 12586 | 110568453 |
| Food allergy | 1005.11 | 198.25 | 244 | 8016 | 19704 | 110561335 |
| Immunodeficiency | 866.27 | 198.25 | 249 | 8011 | 38589 | 110542450 |
| Coeliac disease | 783.61 | 198.25 | 236 | 8024 | 42951 | 110538088 |
| Rash erythematous | 631.91 | 198.25 | 235 | 8025 | 81597 | 110499442 |
| Fluid retention | 631.46 | 198.25 | 244 | 8016 | 94063 | 110486976 |
| Foetal death | 581.84 | 198.25 | 151 | 8109 | 15894 | 110565145 |
| Upper respiratory tract infection | 533.97 | 198.25 | 238 | 8022 | 131090 | 110449949 |
| Bursitis | 526.77 | 198.25 | 235 | 8025 | 129683 | 110451356 |
| Hyperhidrosis | 485.28 | 198.25 | 249 | 8011 | 187049 | 110393990 |
| Prescribed overdose | 421.71 | 198.25 | 179 | 8081 | 87402 | 110493637 |
| Asthma | 383.99 | 198.25 | 236 | 8024 | 250055 | 110330984 |
| Hepatic enzyme increased | 356.19 | 198.25 | 247 | 8013 | 320645 | 110260394 |
| Erythema | 339.06 | 198.25 | 231 | 8029 | 291216 | 110289823 |
| Constipation | 303.08 | 198.25 | 234 | 8026 | 357552 | 110223487 |
| Psoriasis | 299.33 | 198.25 | 164 | 8096 | 139829 | 110441210 |
| Hypersensitivity | 298.98 | 198.25 | 244 | 8016 | 403754 | 110177285 |
| Back pain | 295.56 | 198.25 | 234 | 8026 | 370762 | 110210277 |
| Contraindicated product administered | 291.41 | 198.25 | 198 | 8062 | 248069 | 110332970 |
| Intentional product misuse | 282.18 | 198.25 | 155 | 8105 | 132749 | 110448290 |
| Drug hypersensitivity | 246.53 | 198.25 | 230 | 8030 | 453860 | 110127179 |
| Overdose | 242.67 | 198.25 | 173 | 8087 | 233621 | 110347418 |
| Rheumatoid arthritis | 206.65 | 198.25 | 174 | 8086 | 299439 | 110281600 |
| Product use issue | 202.69 | 198.25 | 175 | 8085 | 311520 | 110269519 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M03BB02 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Oxazol, thiazine, and triazine derivatives |
| ATC | M03BB52 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Oxazol, thiazine, and triazine derivatives |
| ATC | M03BB72 | MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Oxazol, thiazine, and triazine derivatives |
| CHEBI has role | CHEBI:35474 | anxiolytic drug |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:51371 | muscle relaxant |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D009125 | Muscle Relaxants, Central |
| MeSH PA | D009465 | Neuromuscular Agents |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014151 | Anti-Anxiety Agents |
Related Drugs by ATC class:
M03BB Oxazol, thiazine, and triazine derivatives 1 drug
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Anxiety | indication | 48694002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4018260 | VUID |
| N0000146590 | NUI |
| D00268 | KEGG_DRUG |
| 2373 | RXNORM |
| C0008223 | UMLSCUI |
| CHEBI:3619 | CHEBI |
| CHEMBL1200714 | ChEMBL_ID |
| DB01178 | DRUGBANK_ID |
| D002720 | MESH_DESCRIPTOR_UI |
| 2717 | PUBCHEM_CID |
| 7323 | IUPHAR_LIGAND_ID |
| 782 | INN_ID |
| GP568V9G19 | UNII |
| 4413 | MMSL |
| d00909 | MMSL |
| 001447 | NDDF |
| 387400008 | SNOMEDCT_US |
| 71634000 | SNOMEDCT_US |
| 4018260 | VANDF |
Pharmaceutical products:
None